WORK Medical Technology Group LTD
WORK Medical Technology Group LTD (WOK): 1 pipeline candidate · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
D/E 0.65
Lead: Phase 2
1 candidate
N/A
2 buys · 2 sells (180d)
A transparent, data-derived signal for WORK Medical Technology Group LTDacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$57K
Cash
$4.1M
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| psilocybin | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$240
| Holder | Shares | Value |
|---|---|---|
| north star investment management corp. | 200 | $240 |
Frequently asked questions
How many drug candidates are in WORK Medical Technology Group LTD's pipeline?
WORK Medical Technology Group LTD (WOK) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is WORK Medical Technology Group LTD's lead drug candidate?
WORK Medical Technology Group LTD's most advanced tracked candidate is psilocybin (Phase 2) for Post Traumatic Stress Disorder.
What is WORK Medical Technology Group LTD's market capitalization?
WORK Medical Technology Group LTD's market capitalization is approximately $57K.
Who is the CEO of WORK Medical Technology Group LTD?
Mr. Shuang Wu is the chief executive officer of WORK Medical Technology Group LTD (WOK).
Get the full picture on WORK Medical Technology Group LTD
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.